Aim To evaluate the relationship between numerical and categorical immunohistochemical score of Ki-67 and human epidermal growth factor of receptor 2 (HER2) with clinicopathological parameters of breast cancer (BC). Methods The study included 311 patients with invasive BC diagnosed at the Department of Pathology, School of Medicine in Sarajevo, Bosnia and Herzegovina, during the period 2015-2019. The expression level of Ki-67 and HER2 was detected by immunohistochemical analysis. Results The expression of Ki-67, as a numerical variable correlated significantly with tumour grade (p=0.025), progesterone receptor (PR) (p=0.034) and categorical score of HER2 (p=0.028). When Ki-67 was categorized into high (>14%) and low (≤14%) level groups, a statistically significant association was found between Ki-67 level groups and HER2 status (categorical and numerical) (p=0.001 and p=0.043, respectively), as well as significant negative linear correlation with PR (p=0.037). The expression of HER2, as a numerical variable, showed a statistically significant correlation with tumour grade (p=0.038), PR (p=0.025) and categorical Ki-67 (p=0.043). Categorical score of HER2 correlated significantly with age (p=0.025), histologic type (p=0.039), tumour grade (p=0.016), estrogen receptor (ER), (p=0.002) progesterone receptor (PR) (p=0.0001), and categorical and numerical value of Ki-67 (p=0.0001 and p=0.0001, respectively). Conclusion The results demonstrated that the categorical immunohistochemical score of HER2 provided a greater association with clinicopathological parameters than numerical score of BC. Furthermore, a slightly better correlation with clinicopathological parameters was shown by the numerical value than by the categorical score of Ki-67 by applying a cut-off value of 14%
Siegel R, Jemal A. Cancer Facts and Figures. American Cancer Society; 2013.
2.
Perou C, Sørlie T, Eisen M, Van De Rijn M, Jeffrey S, Rees C, et al. Molecular portraits of human breast tumours. Nature. 2000. p. 747–52.
3.
Sørlie T, Perou C, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci. 2001. p. 10869–74.
4.
Cuzick J, Dowsett M, Pineda S, Wale C, Salter J, Quinn E, et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J Clin Oncol. 2011. p. 4273–8.
5.
Soliman N, Yussif S. Ki-67 as a prognostic marker according to breast cancer molecular subtype. Cancer Biol Med. 2016. p. 496–504.
6.
Dowsett M, Nielsen T, ’hern A, Bartlett R, Coombes J, Cuzick R, et al. International Ki-67 in Breast Cancer Working Group. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst. 2011. p. 1656–64.
7.
Hashmi A, Hashmi K, Irfan M, Khan S, Edhi M, Ali J, et al. Ki67 index in intrinsic breast cancer subtypes and its association with prognostic parameters. BMC Res Notes. 2019. p. 605.
8.
Ménard S, Tagliabue E, Campiglio M, Pupa S. Role of HER2 gene overexpression in breast carcinoma. J Cell Physiol. 2000. p. 150–62.
9.
Harari D, Yarden Y. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene. 2000. p. 6102–14.
10.
Lebeau A, Deimling D, Kaltz C, Sendelhofert A, Iff A, Luthardt B, et al. Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. J Clin Oncol. 2001. p. 354–63.
11.
Varga Z, Noske A. Impact of modified 2013 ASCO/ CAP guidelines on HER2 testing in breast Cancer. One Year Experience PLoS One. 2015. p. 140652.
12.
Coates A, Goldhirsch W, Gelber A, Gnant R, Piccart-Gebhart M, Thürlimann M, et al. Tailoring therapiesimproving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Terapy of Early Breast Cancer. Ann Oncol. 2015. p. 1533–46.
13.
Curigliano G, Burstein H, Winer E, Gnant M, Dubsky P, Loibl S, et al. Xu B. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer. Ann Oncol. 2017. p. 1700–12.
14.
Wiesner F, Magener A, Fasching P, Wesse J, Bani M, Rauh C, et al. Ki-67 as a prognostic molecular marker in routine clinical use in breast cancer patients. Breast. 2009. p. 135–41.
15.
Tanei T, Shimomura A, Shimazu K, Nakayama T, Kim S, Iwamoto T, et al. Prognostic significance of Ki-67 index after neoadjuvant chemotherapy in breast cancer. Eur J Surg Oncol. 2011. p. 155–61.
16.
Bottini A, Berruti A, Bersiga A, Brizzi M, Bruzzi P, Aguggini S, et al. Relationship between tumour shrinkage and reduction in Ki67 expression after primary chemotherapy in human breast cancer. Br J Cancer. 2001. p. 1106–12.
17.
Sinn H, Kreipe H. A brief overview of the WHO classification of breast tumors, 4th edition. Breast Care (Basel). 2013. p. 149–54.
18.
Amin M, Edge B, Greene S, Byrd F, Brookland D, Washington R, et al. AJCC Cancer Staging Manual. Springer International Publishing AG; 2018.
19.
Elston C, Ellis I. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with longterm follow-up. Histopathology. 1991. p. 403–10.
20.
Remmele W, Stegner H. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe. 1987. p. 138–40.
21.
Deyarmin B, Kane J, Valente A, Van Laar R, Gallagher C, Shriver C, et al. Effect of ASCO/CAP guidelines for determining ER status on molecular subtype. Ann Surg Oncol. 2013. p. 87–93.
22.
Luporsi E, André F, Spyratos F, Martin P, Jacquemier J, Penault-Llorca F, et al. Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. Breast Cancer Res Treat. 2012. p. 895–915.
23.
Haroon S, Hashmi A, Khurshid A, Kanpurwala M, Mujtuba S, Malik B, et al. Ki67 index in breast cancer: correlation with other prognostic markers and potential in pakistani patients. Asian Pac J Cancer Prev. 2013. p. 4353–8.
24.
Denkert C, Loibl S, Müller B. Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial. Ann Oncol. 2013. p. 2786–93.
25.
Aman N, Doukoure B, Koffi K, Koui B, Traore Z, Kouyate M, et al. Immunohistochemical evaluation of Ki-67 and comparison with clinicopathologic factors in breast carcinomas. Asian Pac J Cancer Prev. 2019. p. 73–9.
26.
Sun J, Chen C, Wei W, Zheng H, Yuan J, Tu Y, et al. Associations and indications of Ki67 expression with clinicopathological parameters and molecular subtypes in invasive breast cancer: A population-based study. Oncol Lett. 2015. p. 1741–8.
27.
Kanyılmaz G, Yavuz B, Aktan M, Karaağaç M, Uyar M, Fındık S. Prognostic importance of Ki-67 in breast cancer and its relationship with other prognostic factors. Eur J Breast Health. 2019. p. 256–61.
28.
Alco G, Bozdogan A, Selamoglu D, Pilanci K, Tuzlali S, Ordu C, et al. Clinical and histopathological factors associated with Ki-67 expression in breast cancer patients. Oncol Lett. 2015. p. 1046–54.
29.
Kilickap S, Kaya Y, Yucel B, Tuncer E, Akgul B, Elagoz N, et al. Higher Ki67 expression associates with unfavorable prognostic factors and shorter survival in breast cancer. Asian Pac J Cancer Prev. 2014. p. 1381–5.
30.
Pinder S, Wencyk P, Sibbering D, Bell J, Elston C, Nicholson R, et al. Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: associations with other prognostic factors and survival. Br J Cancer. 1995. p. 146–9.
31.
Inwald E, Klinkhammer-Schalke M, Hofstädter F, Zeman F, Koller M, Gerstenhauer M, et al. Ki-67 is a prognostic parameter in breast cancer patients: results of large population-based cohort of a cancer registry. Breast Cancer Res Treat. 2013. p. 539–52.
32.
Zhou S, Guo H. Ki-67 expression and significance of different molecular subtypes of breast invasive ductal carcinoma. Zhonghua Yi Xue Za Zhi. 2013. p. 2895–7.
33.
Shapochka D, Zaletok S, Gnidyuk M. Relationship between NF-kappaB, ER, PR, Her2/neu, Ki67, p53 expression in human breast cancer. Exp Oncol. 2012. p. 358–63.
34.
Nishimura R, Osako T, Okumura Y, Hayashi M, Toyozumi Y, Arima N. Ki-67 as a prognostic marker according to breast cancer subtype and a predictor of recurrence time in primary breast cancer. Exp Therapeutic Med. 2010. p. 747–54.
35.
Mendoza G, Portillo A, Olmos-Soto J. Accurate breast cancer diagnosis through real-time PCR her-2 gene quantification using immunohistochemicallyidentified biopsies. Oncol Lett. 2013. p. 295–8.
36.
Wolff A, Hammond M, Schwartz J, Hagerty K, Allred D, Cote R, et al. College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. American Society of Clinical Oncology; 2007. p. 118–45.
37.
Shokouh T, Ezatollah A, Barand P. ER, and PR Status and Their Associations with Tumor Grade and Lymph Node Involvement in Breast Carcinoma Subtypes. Medicine (Baltimore). 2015. p. 1359–64.
38.
Liu Z, Zhang C, Zhuo P, He K, Wang X, Yu Q, et al. Characteristic of ER+/PR-and Ki67 value with breast cancer. Int J Clin Exp Med. 2017. p. 3533–9.
39.
Ding L, Zhang Z, Xu Y, Zhang Y. Ki-67 expression and clinicopathological characteristics of breast cancer in a cohort of northern China female patients. Bioengineered. 2017. p. 383–92.
40.
Soliman N, Yussif S. Ki-67 as a prognostic marker according to breast cancer molecular subtype. Cancer Biol Med. 2016. p. 496–504.
41.
Alzaman A, Mughal S, Alzaman Y, Alzaman E. Correlation between hormone receptor status and age, and its prognostic implications in breast cancer patients in Bahrain. Saudi Med J. 2016. p. 37–42.
42.
Lobbezoo D, Van Kampen R, Voogd A, Dercksen M, Van Den Berkmortel F, Smilde T, et al. Prognosis of metastatic breast cancer subtypes: the hormone receptor/ HER2-positive subtype is associated with the most favorable outcome. Breast Cancer Res Treat. 2013. p. 507–14.
43.
Gabriel C, Domchek S. Breast cancer in young women. Breast Cancer Res. 2010. p. 212.
44.
Liu X, Zheng Y, Qiao C, Qv F, Wang J, Ding B, et al. Expression of SATB1 and HER2 in breast cancer and the correlations with clinicopathologic characteristics. Diagn Pathol. 2015. p. 50.
45.
Aman N, Doukoure B, Koffi K, Koui B, Traore Z, Kouyate M, et al. HER2 overexpression and correlation with other significant clinicopathologic parameters in Ivorian breast cancer women. BMC Clin Pathol. 2019. p. 1.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
,
